loading...

Complexity Communication Scale (CCS)

Brady NC; Thiemann-Bourque K; Olswang L; Dowden P; Saunders M; Fleming K; Marquis J

Distributed by Mapi Research Trust

ProQolid

Distributed by Mapi Research Trust

Basic description

Missed the live webinar? Register here to watch the recording

Assessing Minimally Verbal Communication with the Communication Complexity Scale (CCS), developed to measure expressive communication during a scripted communication sample, or during a live observation.

  • First version published in 2012 and revised version published in 2018
  • The CCS is a 12-point scale that can be applied to various populations and age ranges:
    • in controlled setting with activities designed to elicit specific forms of communication, by using the CCS assessment protocols designed at the University of Kansas (KU CCS ; Brady N, 2012) or other scripted assessment protocols, e.g. the Early Social Communication Scales
    • in natural contexts such as classrooms, playgrounds or work settings
Authors

Brady NC; Thiemann-Bourque K; Olswang L; Dowden P; Saunders M; Fleming K; Marquis J

Copyright
© 2015 The University of Kansas. All Rights Reserved
Objective
To describe the communication status of individuals who communicate primarily presymbolically, including individuals with severe intellectual and developmental disabilities, individuals with autism and typically developing infants. The CCS encompasses 3 levels of early expressive communication behaviors : preintentional and intentional nonsymbolic communication (e.g., gestures, eye gaze, and nonspeech vocalizations) as well as beginning intentional communication (e.g., speech, signs or graphic symbol selection).
Therapeutic area
  • Mental Disorders
  • Behavior and Behavior Mechanisms
  • Nervous System Diseases
  • Pathological Conditions, Signs and Symptoms
Therapeutic indication
  • Developmental Disabilities
  • Communication
  • Intellectual Disability
  • Autistic Disorder
Has been developed and validated with children and adults with intellectual, developmental or multiple disabilities, including autism spectrum disorders, Down syndrom, motor impairments and vision impairments
Type of Clinical Outcome Assessment (COA)
  • clinro ClinRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Brady NC, Fleming K, Romine RS, Holbrook A, Muller K, Kasari C. Concurrent Validity and Reliability for the Communication Complexity Scale. Am J Speech Lang Pathol. 2018 Feb 6;27(1):237-246 (PubMed abstract)

Brady N, Fleming K, Thiemann-Bourque K, Olswang L, Dowden P, Saunders M, & Marquis J. Development of the Communication Complexity Scale. American Journal of Speech-Language Pathology 2012;21(1):16-28 (Full text article)

Access this questionnaire

The user must go through training/certification(for a fee) through the University of Kansas:

Please contact Dr. Nancy Brady at nbrady@ku.edu

All requests have to be submitted through our online request management:

  1. Log in or Register for free
  2. Submit your request (Tutorials are available on our FAQs)
  3. Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Fees may apply to your project.


Contact and conditions of use

Authors

Brady NC; Thiemann-Bourque K; Olswang L; Dowden P; Saunders M; Fleming K; Marquis J

Contact information

Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66

Conditions of use

The user must go through training/certification(for a fee) through the University of Kansas:

Please contact Dr. Nancy Brady at nbrady@ku.edu

All requests have to be submitted through our online request management:

  1. Log in or Register for free
  2. Submit your request (Tutorials are available on our FAQs)
  3. Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Fees may apply to your project.

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.

Languages

Original language(s)

  • English for the USA

Translations

The list of available translations is subject to constant changes and may not be exhaustive. It is provided for information only. Some recently produced translations may not be included in the list below yet. Please do check the status of available translations with Mapi Research Trust / the developers / copyright holders / distributors.

Also, the listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.

The author has selected Mapi/ICON Language Services as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi/ICON Language Services

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.

More information on translations

For information on, or permission to use the translations, please contact Mapi Research Trust

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us